Journal
ANNALS OF NEUROLOGY
Volume 81, Issue 5, Pages 749-753Publisher
WILEY
DOI: 10.1002/ana.24921
Keywords
-
Categories
Funding
- Stichting Alzheimer Nederland
- Stichting VUmc Fonds
- Stichting Dioraphte
- Boehringer Ingelheim Pharma, Germany
- Memorabel grant program of the Netherlands Organization for Health Research and Development (ZonMW grant) [733050506]
Ask authors/readers for more resources
We studied whether continuous lower normal cerebrospinal fluid (CSF) amyloid beta 1-42 (>= 640pg/ml) levels were related with rate of clinical progression in a sample of 393 nondemented memory clinic patients. Lower normal levels were associated with faster clinical progression, and this depended on baseline cognitive status (subjective cognitive decline: hazard ratio [HR] = 0.57, p < 0.05; mild cognitive impairment: HR = 0.19, p < .01), indicating that normal CSF amyloid levels do not exclude incident Alzheimer disease. These findings suggest that research on preclinical markers for Alzheimer disease should take the continuum of CSF amyloid beta 1-42 levels within the normal range into account.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available